Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA DTC Study Should Use Real Ads, Be More Conversational – AstraZeneca

Executive Summary

AstraZeneca is asking FDA to incorporate a more qualitative approach in the initial phase of its planned evaluation of the "brief summary" section of direct-to-consumer print advertising

You may also be interested in...



Risk Disclosure In Rx Ad “Brief Summary” To Be Examined By Modified FDA Study

FDA is modifying its upcoming studies of brief summaries in Rx advertising to assess whether changes such as organizing side effects into short- and long-term categories would aid comprehension

Risk Disclosure In Rx Ad “Brief Summary” To Be Examined By Modified FDA Study

FDA is modifying its upcoming studies of brief summaries in Rx advertising to assess whether changes such as organizing side effects into short- and long-term categories would aid comprehension

DTC Risk Disclosures Examined By FDA; Do Minor Risks Swamp Major Ones?

FDA will evaluate how the presence of minor safety risks in the brief summary of print direct-to-consumer advertisements impacts consumer comprehension of major risks

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS045741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel